홈
탐색
nav.journalClub
트렌드
더보기
synapse
⌘+K
언어
한국어
한국어
March 3, 2026
Journey of Relapsed or Refractory Multiple Myeloma (RRMM) after Quadruple-Class Exposure (QCEx): Poor Outcomes and High Attrition
DH
Doris K. Hansen
LW
Lin Wang
FG
Fangyi Gu
Bristol-Myers Squibb (Germany)
See all
Key Points
Patients with relapsed refractory multiple myeloma (RRMM) experience significant treatment-related attrition after quadruple-class exposure.
Outcomes highlight a concerning trend, with over 60% reporting inadequate response to therapies after QCEx.
Observational analysis reveals patterns in treatment efficacy and patient experiences across multiple clinical settings.
These findings emphasize the urgent need to reevaluate treatment strategies for enhancing patient outcomes in RRMM.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Hansen et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76022c6e9836116a2c965
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.614
Journey of Relapsed or Refractory Multiple Myeloma (RRMM) after Quadruple-Class Exposure (QCEx): Poor Outcomes and High Attrition | Synapse